No Data
No Data
Immunome, Inc.'s (NASDAQ:IMNM) Institutional Investors Lost 6.0% Last Week but Have Benefitted From Longer-term Gains
Key Insights Institutions' substantial holdings in Immunome implies that they have significant influence over the company's share price 52% of the business is held by the top 11 shareholders
Immunome Insiders Added US$2.67m Of Stock To Their Holdings
STALICLA Appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9, 2024 – STALICLA SA, a
Express News | Immunome Appoints Phil Tsai as Chief Technical Officer
Evaluating Immunome: Insights From 4 Financial Analysts
In the preceding three months, 4 analysts have released ratings for Immunome (NASDAQ:IMNM), presenting a wide array of perspectives from bullish to bearish.The following table provides a quick overvie
Immunome Initiated at Overweight by Piper Sandler
Immunome Initiated at Overweight by Piper Sandler
No Data